A typical AOD 9604 cycle runs 8–12 weeks at 250–500 mcg daily. Learn cycle length, dosage, reconstitution, side effects, and how it compares to tesamorelin.
An AOD 9604 cycle typically lasts 8 to 12 weeks and uses 250 to 500 mcg of peptide per day, injected subcutaneously. AOD 9604 — also called HGH fragment 176-191 — is a synthetic piece of human growth hormone that researchers have studied for fat metabolism, so cycle plans come from study protocols and user logs rather than approved medical guidance. AOD 9604 is not FDA-approved for human use in the United States.
What AOD 9604 Is and Why People Cycle It
AOD 9604 is a 16-amino-acid fragment of the C-terminal end of human growth hormone. Scientists altered the fragment's structure to extend its half-life and to keep it from binding the full hGH receptor the way complete growth hormone does.
Early lab work reported that the peptide stimulated lipolysis — the breakdown of stored fat — without the blood sugar and IGF-1 shifts typically seen with full-dose HGH. That difference is the main reason people treat it as a targeted fat-loss peptide rather than a general growth hormone.
"Cycling" means running the peptide for a set number of weeks and then taking time off. The rationale is borrowed from other hormone protocols: limit receptor desensitization, let natural signaling reset, and judge results over a defined window. There is no clinical evidence that AOD 9604 requires cycling at all.
How Long Should an AOD 9604 Cycle Be?
Most online protocols settle on 8 to 12 weeks, which is the range behind nearly every search for aod-9604 cycle length. Shorter runs of 4 to 6 weeks appear too, usually as a trial to check tolerance.
| Cycle length | How it is used | Notes |
|---|---|---|
| 4–6 weeks | Short trial run | Used to test tolerance and the injection routine |
| 8–12 weeks | Most common protocol | Appears in the majority of user logs and forum plans |
| 16+ weeks | Extended run | Less common; no data supporting longer exposure |
AOD 9604 has no officially recommended cycle length, because it has no approved human dosing. Any number you see online is a convention, not a clinical standard.
After a cycle, most users plan 4 to 8 weeks off before considering another round. That off period is a habit rather than a requirement established by trials.
AOD 9604 Dosage and Injection Timing
The aod 9604 dosage discussed most often is 250 to 500 mcg per day. Published research has used both single daily doses and split doses, and higher amounts have not produced proportionally better results in the human data that exists.
| Daily dose | Frequency | Common timing |
|---|---|---|
| 250 mcg | Once per day | Morning, fasted |
| 300 mcg | Once per day | Morning, fasted |
| 500 mcg | Once daily or 250 mcg twice | Morning and pre-workout |
Injections are subcutaneous — into the abdomen or outer thigh — and sites should be rotated to reduce irritation. Some users inject while fasted and wait 30 minutes before eating, based on the idea that insulin blunts lipolysis. That timing has not been tested directly with AOD 9604.
AOD 9604 Reconstitution and Storage
Most AOD 9604 arrives as a lyophilized powder that must be mixed with bacteriostatic water before use. Get aod 9604 reconstitution wrong and you either damage the peptide or draw the wrong dose.
- Clean the stoppers of both vials with alcohol and let them dry.
- Draw the desired volume of bacteriostatic water into a syringe.
- Inject the water slowly down the inside wall of the peptide vial instead of directly onto the powder.
- Swirl gently until dissolved. Never shake, which can degrade the peptide.
- Refrigerate at 2–8 °C, protect from light, and use within roughly four to six weeks.
The math matters as much as the technique. A 2 mg vial mixed with 1 mL of water gives 2,000 mcg per mL, so a 250 mcg dose equals 0.125 mL, or 12.5 units on a U-100 insulin syringe.
AOD 9604 vs Tesamorelin
These two peptides are compared constantly because both are linked to fat reduction, but they are not close substitutes. The aod 9604 vs tesamorelin comparison comes down to approval status, mechanism, and the strength of the evidence.
| Factor | AOD 9604 | Tesamorelin |
|---|---|---|
| FDA status | Not approved for human use | Approved (Egrifta) for HIV-associated lipodystrophy |
| Mechanism | hGH fragment 176-191; acts on fat tissue | GHRH analog; raises endogenous growth hormone |
| IGF-1 effect | Reported as minimal in early studies | Raises IGF-1 |
| Typical dose | 250–500 mcg daily | 1–2 mg daily |
| Evidence base | Small early trials; obesity results were weak | Phase III trials and full FDA review |
Stacking AOD 9604 With Tirzepatide
Interest in aod 9604 with tirzepatide comes from people already using a prescription GLP-1/GIP medication who want to add a fat-targeting peptide. No clinical trial has tested this combination, and the two work through entirely different pathways.
Tirzepatide suppresses appetite and slows gastric emptying; AOD 9604 is theorized to act locally on fat cells. Because tirzepatide already produces substantial weight loss on its own, stacking makes it nearly impossible to tell which compound is doing what.
Anyone considering this combination should talk to a prescribing physician first. Combining an unapproved research peptide with a prescription drug introduces interactions and side effects that have never been characterized.
Reported Benefits, Side Effects, and Results
User reports describe modest fat loss, mostly around the abdomen, along with reduced appetite in some cases. Reported side effects are usually mild: injection site redness, headache, and occasional nausea.
The more important finding comes from the research side. Publicly reported Phase II results for AOD 9604 in obesity did not show clinically meaningful weight loss, which is why development stalled. AOD 9604 failed to outperform placebo in the human weight-loss data that has been made public.
Safety, Legal Status, and Bottom Line
AOD 9604 is sold as a research chemical, not a medication. Products labeled "research use only" are not held to pharmaceutical purity or sterility standards, so the contents of the vial are not guaranteed.
- AOD 9604 is not FDA-approved for human use in the United States.
- Most AOD 9604 cycles run 8 to 12 weeks at 250–500 mcg per day.
- Tesamorelin has FDA approval and Phase III data; AOD 9604 has neither.
- No trial has tested AOD 9604 combined with tirzepatide.
- Anyone using injectable peptides should involve a healthcare professional and get baseline bloodwork.
Bottom line: an AOD 9604 cycle is a convention built on forum habits, not clinical guidance. The peptide is not approved, its human weight-loss results were disappointing, and the safest move is to discuss any weight-loss plan with a licensed clinician.
Frequently Asked Questions
How long should an AOD 9604 cycle last?
Most user protocols run 8 to 12 weeks, with some shorter 4 to 6 week trial runs. There is no official recommended cycle length, because AOD 9604 has never been approved for human use and has no established clinical dosing. Most people then take 4 to 8 weeks off before considering another round.
What is a typical AOD 9604 dosage?
The dose discussed most often is 250 to 500 mcg per day, injected subcutaneously, usually in the morning while fasted. Published research used both once-daily and split dosing, and higher amounts have not produced clearly better results in the human data that exists. A 2 mg vial mixed with 1 mL of bacteriostatic water makes a 250 mcg dose equal to 12.5 units on a U-100 syringe.
Is AOD 9604 FDA-approved for weight loss?
No. AOD 9604 is not FDA-approved for any human use in the United States and is sold only as a research chemical. Publicly reported Phase II obesity results did not show clinically meaningful weight loss, which is a major reason development stopped. Talk with a licensed healthcare professional before using any unapproved peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.